A Phase I Dose-Escalation Study of Intermittent, Once Weekly, and Continuous Daily Oral OSI-027 Dosing in Patients With Advanced Solid Tumors or Lymphoma.
Phase of Trial: Phase I
Latest Information Update: 22 Mar 2016
At a glance
- Drugs OSI 027 (Primary)
- Indications Lymphoma; Solid tumours
- Focus Adverse reactions
- Sponsors Astellas Pharma
- 22 Mar 2016 Results published in the British Journal of Cancer
- 01 Feb 2013 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 07 Jul 2012 Planned number of patients changed from 130 to 160 as reported by ClinicalTrials.gov.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History